Targeted short-lived drug delivery

• US 20090130017A1
• Filed: 10/29/2008
• Published: 05/21/2009
• Est. Priority Date: 11/19/2007
• Status: Abandoned Application

• Current Assignee: Searete LLC (Intellectual Ventures LLC)
• Original Assignee: Searete LLC (Intellectual Ventures LLC)
• Inventors: Allen, Paul G., Ishikawa, Muriel Y., Myhrvold, Nathan P., Tegreene, Clarence T., Boyden, Edward S., Wood, Lowell L. JR., Hyde, Roderick A., Malaska, Stephen L.
• Application Number:
  US12/290,457
• Publication Number:
  US 20090130017A1
• Time in Patent Office: Days
• US Class Current: 424/1.110
• CPC Class Codes: A61K 31/137 Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• CPC Class Codes: A61K 31/40 having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• CPC Class Codes: A61K 31/7048 having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin , digitoxin or digoxin
• CPC Class Codes: A61K 31/7105 Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• CPC Class Codes: A61K 31/727 Heparin; Heparan
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61K 51/1255 Granulates, agglomerates, microspheres
• CPC Class Codes: A61L 2300/258 Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
• CPC Class Codes: A61L 2300/406 Antibiotics
• CPC Class Codes: A61L 2300/41 Anti-inflammatory agents, e.g. NSAIDs
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/42 Anti-thrombotic agents, anticoagulants, anti-platelet agents
• CPC Class Codes: A61L 2300/602 Type of release, e.g. controlled, sustained, slow
• CPC Class Codes: A61L 2300/62 Encapsulated active agents, e.g. emulsified droplets
• CPC Class Codes: A61L 29/16 Biologically active materials, e.g. therapeutic substances A61L29/048 takes precedence
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

An aspect of the disclosure includes a system for delivering therapeutic agents. In an embodiment, the system includes an implantable medical device comprising at least one reservoir that holds at least one therapeutic agent. Additionally the device includes a delivery mechanism that provides non-systemic in vivo delivery of the at least one therapeutic agent to a local area of an animal in a therapeutically-effective concentration, wherein the therapeutically-effective concentration is in excess of a concentration that would produce a toxic effect when administered systemically to the animal. Furthermore, the at least one therapeutic agent has short half-life. A further aspect of the disclosure includes a method of delivering a therapeutic agent in vivo at non-systemic high doses to a localized area of an animal.

Claims

1. An implantable medical device, comprising:

at least one reservoir that holds at least one therapeutic agent;

a delivery mechanism configured to provide non-systemic delivery of the at least one therapeutic agent to a local area of an animal in a therapeutically-effective concentration;

wherein the therapeutically-effective concentration is in excess of a concentration that would produce a toxic effect if administered systemically to the animal; and

wherein the at least one therapeutic agent has a half-life of about 5 hours or less.

2. The device of claim 1, wherein the at least one therapeutic agent includes anti-coagulants of blood.

3. The device of claim 2, wherein the anti-coagulants of blood include tissue plasminogen activator or heparin.

4. The device of claim 1, wherein the at least one therapeutic agent includes an anti-cancer agent.

5. The device of claim 4, wherein the at least one therapeutic agent is selected from a group consisting of podophyllotoxin, etoposide, chlorambucil, cisplatin, oxaliplatin, carboplatin and OGX-011.

6. The device of claim 1, wherein the at least one therapeutic agent includes an anti-inflammatory agent.

7. The device of claim 1, wherein the at least one therapeutic agent includes at least one agent for gene therapy of diseases.

8. The device of claim 7, wherein the at least one agent for gene therapy includes a RNA, siRNA, RNAi, or DNA.

9. The device of claim 1, wherein the at least one therapeutic agent has a half-life of about 4 hours or less.

10. The device of claim 1, wherein the at least one therapeutic agent has a half-life of about 3 hours or less.

11. The device of claim 1, wherein the at least one therapeutic agent has a half-life of about 2 hours or less.

12. The device of claim 1, wherein the at least one therapeutic agent has a half-life of about 1 hour or less.

13. The device of claim 1, wherein the at least one therapeutic agent includes at least one agent to treat cardiac arrhythmia.

14. The device of claim 13, wherein the at least one agent to treat cardiac arrhythmia is selected from a group consisting of lidocaine, atropine and adenosine.

15. The device of claim 1, wherein the at least one therapeutic agent includes at least one agent to treat a neurological or behavioral disorder.

16. The device of claim 15, wherein the at least one agent to treat a neurological disorder or behavioral disorder includes venlafaxine.

17. The device of claim 1, wherein the at least one therapeutic agent includes at least one agent to treat human airway passages.

18. The device of claim 17, wherein the at least one agent to treat human airway passages includes albuterol.

19. The device of claim 1, wherein the at least one therapeutic agent includes at least one antibiotic agent.

20. The device of claim 19, wherein the at least one antibiotic agent includes erythromycin or its derivatives.

21. The device of claim 1, wherein the at least one therapeutic agent includes at least one cholesterol-lowering therapeutic agent.

22. The device of claim 21, wherein the at least one cholesterol-lowering therapeutic agent includes atorvastatin.

23. The device of claim 1, wherein the at least one reservoir includes one of a lipid bilayer, a microcapsule, a liposome, a granule, capsule or a radioactive seed.

24. The device of claim 1, wherein the implantable device further comprises at least one of a catheter, a radioactive seed, a stent, a needle, a syringe, a trocar, a microchip or a tube.

25-47. -47. (canceled)

48. A system, comprising:

a means for providing non-systemic delivery of at least one therapeutic agent to a local area of an animal in a therapeutically-effective concentration, wherein the therapeutically-effective concentration is in excess of a concentration that would produce a toxic effect if administered systemically to the animal, and wherein the at least one therapeutic agent has a half-life of about 5 hours or less.

49. The system of claim 48, wherein a means for providing a non-systemic delivery of at least one therapeutic agent to a local area of an animal includes delivery to at least one of a joint, a heart, a kidney, a lung, a brain, a liver, a spleen, a blood vessel, a vein, a capillary, a stomach, an intestine, a duodenum, a fallopian tube, non-vasculaturized area or a bone.

50. The system of claim 48, wherein the at least one therapeutic agent includes an anti-coagulant of blood.

51. The system of claim 48, wherein the anti-coagulants of blood include tissue plasminogen activator or heparin.

52. The system of claim 48, wherein the at least one therapeutic agent includes an anti-cancer agent.

53. The system of claim 52, wherein the at least one anti-cancer agent includes podophyllotoxin, etoposide, chlorambucil, cisplatin, oxaliplatin, carboplatin or OGX-011.

54. The system of claim 48, wherein the at least one therapeutic agent includes an anti-inflammatory agent.

55. The system of claim 48, wherein the at least one therapeutic agent has a half-life of about 4 hours or less.

56. The system of claim 48, wherein the at least one therapeutic agent has a half-life of about 3 hours or less.

57. The system of claim 48, wherein the at least one therapeutic agent has a half-life of about 2 hours or less.

58. The system of claim 48, wherein the at least one therapeutic agent has a half-life of about 1 hour or less.

59. The system of claim 48, wherein the at least one therapeutic agent includes at least one agent to treat cardiac arrhythmia.

60. The system of claim 59, wherein the at least one agent to treat cardiac arrhythmia includes lidocaine, atropine or adenosine.

61. The system of claim 48, wherein the at least one therapeutic agent includes at least one agent to treat a neurological disorder or behavioral disorder.

62. The system of claim 61, wherein the at least one agent to treat neurological disorder or behavioral disorder includes venlafaxine.

63. The system of claim 48, wherein the at least one therapeutic agent includes at least one agent to treat human airway passages.

64. The system of claim 63, wherein the at least one agent to treat human airway passages includes albuterol.

65. The system of claim 48, wherein the at least one therapeutic agent includes at least one antibiotic agent.

66. The system of claim 65, wherein the at least one antibiotic agent includes at least one of erythromycin or a derivative thereof.

67. The system of claim 48, wherein the at least one therapeutic agent includes at least one cholesterol-lowering therapeutic agent.

68. The system of claim 67, wherein the at least one cholesterol-lowering therapeutic agent includes atorvastatin.

69-91. -91. (canceled)